<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1052243361488264&amp;ev=PageView&amp;noscript=1">

Antibody-dependent cell cytotoxicity (ADCC)

Antibody-dependent cell cytotoxicity (ADCC) allow us to evaluate the cytotoxic function of effector cells, for instance, NK cells that have the capability to kill cancer cells. Antibody-dependent cell cytotoxicity requires specific antibodies that bind to target cells while exposing the FcR; the cells with cytotoxic activity engage the FcR and this triggers the cytolytic killing of the target cells. Antibody-dependent cell cytotoxicity (ADCC) bridges adaptive and innate immune response and it is the main mechanism known to be effective against viral infections and cancer in vivo. If we are evaluating therapeutic antibodies, peripheral blood mononuclear cells (PBMC) can be used as effector cells. The concentration, quality and features of the components are carefully selected for this mechanistic assay, and the outcome is confirmed and quantified by flow cytometry.

At FlowMetric, we have the expertise to perform Antibody-dependent cell cytotoxicity (ADCC) assays in support of your research and drug development.

 

Speak With a Cytometry Expert

optimal assay validation panel design
 


FlowMetric Blog Posts



Receive Updates By Email